Orbimed Advisors LLC Corvus Pharmaceuticals, Inc. Transaction History
Orbimed Advisors LLC
- $2.8 Billion
- Q2 2025
A detailed history of Orbimed Advisors LLC transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Orbimed Advisors LLC holds 7,165,006 shares of CRVS stock, worth $32.2 Million. This represents 1.02% of its overall portfolio holdings.
Number of Shares
7,165,006
Previous 6,943,654
3.19%
Holding current value
$32.2 Million
Previous $22.1 Million
29.8%
% of portfolio
1.02%
Previous 0.69%
Shares
7 transactions
Others Institutions Holding CRVS
# of Institutions
100Shares Held
38.9MCall Options Held
98.5KPut Options Held
226K-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct7.04MShares$31.7 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.28MShares$14.8 Million0.0% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$14.7 Million9.69% of portfolio
-
Rtw Investments, LP New York, NY2.68MShares$12.1 Million0.16% of portfolio
-
Vivo Capital, LLC Palo Alto, CA2.23MShares$10.1 Million1.89% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $209M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...